SELENOP

Summary

SELENOP (selenoprotein P, HGNC:10751) is a protein-coding gene on chromosome 5p12, encoding Selenoprotein P (P49908). Might be responsible for some of the extracellular antioxidant defense properties of selenium or might be involved in the transport of selenium.

This gene encodes a selenoprotein that is predominantly expressed in the liver and secreted into the plasma. This selenoprotein is unique in that it contains multiple selenocysteine (Sec) residues per polypeptide (10 in human), and accounts for most of the selenium in plasma. It has been implicated as an extracellular antioxidant, and in the transport of selenium to extra-hepatic tissues via apolipoprotein E receptor-2 (apoER2). Mice lacking this gene exhibit neurological dysfunction, suggesting its importance in normal brain function. Sec is encoded by the UGA codon, which normally signals translation termination. The 3’ UTRs of selenoprotein mRNAs contain a conserved stem-loop structure, designated the Sec insertion sequence (SECIS) element, that is necessary for the recognition of UGA as a Sec codon, rather than as a stop signal. The mRNA for this selenoprotein contains two SECIS elements. The use of alternative polyadenylation sites, one located in between the two SECIS elements, results in two populations of mRNAs containing either both (predominant) or just the upstream SECIS element (PMID:27881738). Alternatively spliced transcript variants have also been found for this gene.

Source: NCBI Gene 6414 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 31 total
• MANE Select transcript: NM_005410

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10751
Approved symbol	SELENOP
Name	selenoprotein P
Location	5p12
Locus type	gene with protein product
Status	Approved
Aliases	SeP, SELP, SEPP
Ensembl gene	ENSG00000250722
Ensembl biotype	protein_coding
OMIM	601484
Entrez	6414

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 6 retained_intron, 6 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000505309, ENST00000506078, ENST00000506577, ENST00000507920, ENST00000508937, ENST00000509276, ENST00000510650, ENST00000510965, ENST00000511224, ENST00000512980, ENST00000513303, ENST00000514218, ENST00000514403, ENST00000514985, ENST00000515626

RefSeq mRNA: 3 — MANE Select: NM_005410 NM_001085486, NM_001093726, NM_005410

CCDS: CCDS43311

Canonical transcript exons

ENST00000514985 — 5 exons

Exon	Start	End
ENSE00002045187	42811836	42811892
ENSE00002075157	42799880	42801331
ENSE00003463317	42808151	42808366
ENSE00003585566	42804656	42804773
ENSE00003653479	42806896	42807108

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 99.95.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 149.2317 / max 10203.7372, expressed in 1340 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
61503	147.6171	1336
61500	0.4142	167
61505	0.3224	144
61501	0.3017	133
61502	0.2568	110
61508	0.1199	45
61504	0.0858	44
61507	0.0594	27
61506	0.0544	8

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	99.95	gold quality
germinal epithelium of ovary	UBERON:0001304	99.90	gold quality
superficial temporal artery	UBERON:0001614	99.89	gold quality
parietal pleura	UBERON:0002400	99.87	gold quality
pleura	UBERON:0000977	99.85	gold quality
caput epididymis	UBERON:0004358	99.85	gold quality
inferior vagus X ganglion	UBERON:0005363	99.84	gold quality
visceral pleura	UBERON:0002401	99.82	gold quality
corpus epididymis	UBERON:0004359	99.81	gold quality
mammary duct	UBERON:0001765	99.80	gold quality
substantia nigra pars reticulata	UBERON:0001966	99.80	gold quality
subthalamic nucleus	UBERON:0001906	99.79	gold quality
corpus callosum	UBERON:0002336	99.79	gold quality
mucosa of sigmoid colon	UBERON:0004993	99.79	gold quality
lower lobe of lung	UBERON:0008949	99.79	gold quality
skin of hip	UBERON:0001554	99.78	gold quality
mucosa of paranasal sinus	UBERON:0005030	99.77	gold quality
seminal vesicle	UBERON:0000998	99.76	gold quality
right lobe of liver	UBERON:0001114	99.76	gold quality
synovial joint	UBERON:0002217	99.75	gold quality
gall bladder	UBERON:0002110	99.74	gold quality
lateral globus pallidus	UBERON:0002476	99.73	gold quality
trabecular bone tissue	UBERON:0002483	99.73	gold quality
substantia nigra pars compacta	UBERON:0001965	99.72	gold quality
upper leg skin	UBERON:0004262	99.71	gold quality
medulla oblongata	UBERON:0001896	99.70	gold quality
liver	UBERON:0002107	99.70	gold quality
trigeminal ganglion	UBERON:0001675	99.69	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	99.68	gold quality
colonic mucosa	UBERON:0000317	99.67	gold quality

Single-cell (SCXA)

Detected in 34 experiment(s), a significant marker in 30.

Experiment	Marker?	Max mean expression
E-MTAB-6678	yes	9451.33
E-CURD-112	yes	5803.48
E-GEOD-125970	yes	5184.36
E-MTAB-8322	yes	4984.74
E-MTAB-8410	yes	4296.20
E-MTAB-8221	yes	2746.91
E-GEOD-84465	yes	2589.90
E-CURD-126	yes	2513.35
E-HCAD-4	yes	2421.62
E-GEOD-75688	yes	2381.15
E-MTAB-8530	yes	1454.88
E-GEOD-180759	yes	1272.61
E-HCAD-32	yes	691.42
E-HCAD-1	yes	88.16
E-HCAD-25	yes	63.47

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXO1, FOXO3, HNF4A, MTA2, NR3C1, SMAD3, SMAD4, SP1

miRNA regulators (miRDB)

69 targeting SELENOP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-2052	99.79	69.37	2031
HSA-MIR-577	99.78	69.13	2479
HSA-MIR-3150A-3P	99.76	64.44	1640
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-5002-5P	99.76	70.84	1763
HSA-MIR-3617-5P	99.75	69.41	1968
HSA-MIR-641	99.75	69.35	1975
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-4677-5P	99.70	70.09	1940

Literature-anchored findings (GeneRIF, showing 40)

• A DNA-repeat structure within the promoter contains a functionally relevant polymorphism and is genetically unstable under conditions of mismatch repair deficiency (PMID:12173025)
• selenoprotein P functions as a Se-supply protein, delivering Se to the cells (PMID:12423375)
• SePP-like immunoreactivity localizes to neurons and ependymal cells and thus appears strategically situated for maintenance and control of selenium-dependent anti-oxidative defense systems. (PMID:17245539)
• SePmRNA expression in the tissues of normal liver and hepatocellular carcinoma (HCC) is significantly different, suggesting that SeP might play a role in the occurrence and development of HCC. (PMID:17511039)
• Results reveal two common functional nucleotide polymorphisms within the human selenoprotein P gene that may predict behavior of biomarkers of selenium status and response to supplementation and thus susceptibility to disease. (PMID:17536041)
• Both non-glycosylated and partially glycosylated SeP is utilised as selenium donor by target cells. (PMID:17937618)
• local Sepp expression is required to maintain selenium content in selenium-privileged tissues such as brain and testis during dietary selenium restriction (PMID:17961124)
• selenoprotein P reduces lipid hydroperoxides and maintains the viability of myofibroblasts. a novel pathophysiologic function of myofibroblasts as a generator of lipid hydroperoxides, and a self-defense mechanism against self-generated oxidative stress. (PMID:17986007)
• Four variants in SEPP1 were significantly associated with advanced colorectal adenoma risk. (PMID:18483336)
• selenoprotein P expression was low in gastric adenocarcinoma tissues compared with control tissues (PMID:19215687)
• Data conclude that functional polymorphisms in the SEPP-1 gene influence the proportion of SePP isoforms in plasma. (PMID:19453253)
• The glucocorticoid receptor inhibits selenoprotein P transactivation via response elements; the finding provides insight into a potential mechanism of selenium redistribution during development. (PMID:19513589)
• In a study of 817 randomly selected adult Danes, the median selenoprotein P level in serum was 2.72 (2.18-3.49) mg/L. Serum selenoprotein P increased with age and was higher in men than in women. (PMID:19747622)
• Early decrease in Sel-P plasma concentrations was specifically observed in septic shock and was similar in SIRS patients whereas GPx activity remained unchanged. (PMID:19779296)
• tear SeP is a key molecule to protect the ocular surface cells against environmental oxidative stress (PMID:20360971)
• Our findings demonstrate that Selenoprotein P protects neuronal cells from amyloid beta-induced toxicity, suggesting a neuroprotective role for SelP in preventing neurodegenerative disorders. (PMID:20521393)
• Inflammation of the intestinal mucosa causes a decline in locally produced selenoprotein P in the colon that eventually may contribute to the emergence of inflammatory bowel disease-related colorectal cancer. (PMID:20542496)
• The present results show no significant difference in genotype and allele distribution of SNP r25191g/a between individuals with Kashin-Beck disease and controls. (PMID:20565998)
• These findings suggest an association between the individual selenoprotein concentration and the presence of diabetes. (PMID:20875901)
• Using serial analysis of gene expression and DNA chip methods, the study found that hepatic SeP mRNA levels correlated with insulin resistance in humans. (PMID:21035759)
• Selenoprotein P levels in prostate cells determine basal reactive-oxygen-species levels and H2O2-induced cytotoxicity. Deregulation of selenoprotein P during prostate carcinogenesis may increase free radicals, thus promoting tumor development. (PMID:21456065)
• Circulating SeP concentrations were elevated in patients with glucose metabolism dysregulation and were related to various cardiometabolic parameters including insulin resistance, inflammation, and atherosclerosis. (PMID:21677040)
• Circulating selenoprotein P levels were positively correlated with fasting plasma glucose and negatively associated with both total and high-molecular adiponectin in type 2 diabetics. (PMID:22496878)
• Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett’s esophagus: results from biomarkers and genetic variants. (PMID:22715394)
• hepatocellular SAM-dependent protein methylation is required for both SEPP1 and gluconeogenic enzyme expression and that inhibition of protein arginine methylation might provide a route to therapeutic interventions in type II diabetes. (PMID:22932905)
• Higher tumor grade and tumor stage at diagnosis correlated to lower SePP and Se concentrations. (PMID:23056383)
• SEPP1 genetic variation was associated with prostate cancer incidence; replication of these results in an independent dataset is necessary. (PMID:23129481)
• This study demonistrated that Sepp1 in midbrain was expressed in neurons of the substantia nigra (SN), and expression was concentrated within the centers of Lewy bodies, the pathological hallmark of Parkinson disease (PMID:23268326)
• We speculate that there could be a feedback regulation between hepatic Sepp1 and pancreatic insulin and that increased circulating Sepp1 might be the result rather than the cause of abnormal glucose metabolism.[Review] (PMID:23760059)
• These results demonstrate that SEPP1 represents a previously unrecognized regulator of Polychlorinated biphenyl-induced biological effects. (PMID:23770201)
• The data provide evidence that single nucleotide polymorphisms in SEPP1 and GPX1 modulate risk of breast cancer. (PMID:24039907)
• AMPK activators ameliorated carrageenan-induced insulin resistance via SeP inhibition. (PMID:24055274)
• Sepp1 secreted from epithelial cells may support the intestinal immune system by providing immune cells (including plasma cells) with selenium (PMID:24157689)
• Genetic variants in selenoprotein P plasma 1 gene (SEPP1) are associated with fasting insulin and first phase insulin response in Hispanics (PMID:24161883)
• metformin decreases binding of FoxO3a, a direct target of AMPK, to the SEPP1 promoter. (PMID:24257750)
• data suggest that SEPP1 alters breast cancer risk among women with higher levels of NA ancestry (PMID:24278290)
• SePP is not only involved in Selenium transport to testes supporting GPX4 biosynthesis but it also becomes secreted into seminal plasma. (PMID:24361887)
• The histidine-rich domain of selenoprotein P is capable of binding Cu ions in both oxidation states of Cu(+) and Cu(2+) with high affinity and of modulating Cu(+) and Cu(2+)-mediated ABETA aggregation, reactive oxygen species production, neurotoxicity. (PMID:24437729)
• SEPP1 rs7579 was found to be associated with lower risk of advanced prostate cancer. (PMID:24563517)
• Elevated SeP concentrations are independently associated with a reduced risk of MetS in children (PMID:24638201)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Selenop	ENSMUSG00000064373
rattus_norvegicus	Selenop	ENSRNOG00000053086

Protein

Protein identifiers

Selenoprotein P — P49908 (reviewed: P49908)

All UniProt accessions (4): A0A182DWH7, A0A182DWH8, P49908, R4GMT5

UniProt curated annotations — full annotation on UniProt →

Function. Might be responsible for some of the extracellular antioxidant defense properties of selenium or might be involved in the transport of selenium. May supply selenium to tissues such as brain and testis.

Subcellular location. Secreted.

Tissue specificity. Made in the liver and heart and secreted into the plasma. It is also found in the kidney.

Post-translational modifications. Phosphorylation sites are present in the extracellular medium.

Domain organisation. The C-terminus is not required for endocytic uptake in the proximal tubule epithelium.

Similarity. Belongs to the selenoprotein P family.

RefSeq proteins (3): NP_001078955, NP_001087195, NP_005401* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007671	Selenoprotein-P_N	Domain
IPR007672	SelP_C	Domain
IPR037941	SeP	Family

Pfam: PF04592, PF04593

UniProt features (32 total): non-standard amino acid 10, glycosylation site 6, sequence variant 5, sequence conflict 3, compositionally biased region 3, region of interest 2, signal peptide 1, chain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

No AlphaFold model available for P49908 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 266

Glycosylation sites (6): 46, 83, 119, 128, 174, 338

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-114608	Platelet degranulation
R-HSA-109582	Hemostasis
R-HSA-76002	Platelet activation, signaling and aggregation
R-HSA-76005	Response to elevated platelet cytosolic Ca2+

MSigDB gene sets: 679 (showing top): VALK_AML_WITH_FLT3_ITD, GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, GSE45365_NK_CELL_VS_BCELL_UP, GOBP_REGULATION_OF_CELL_ACTIVATION, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, MULLIGHAN_NPM1_SIGNATURE_3_UP, FREAC2_01, WALLACE_PROSTATE_CANCER_RACE_UP, GOBP_HETEROPHILIC_CELL_CELL_ADHESION, GOBP_BEHAVIOR, HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHOCYTE_DN, MODULE_255, GOBP_INFLAMMATORY_RESPONSE, GOBP_RESPONSE_TO_PEPTIDE, XU_GH1_AUTOCRINE_TARGETS_UP

GO Biological Process (7): selenium compound metabolic process (GO:0001887), response to oxidative stress (GO:0006979), brain development (GO:0007420), locomotory behavior (GO:0007626), post-embryonic development (GO:0009791), response to selenium ion (GO:0010269), regulation of growth (GO:0040008)

GO Molecular Function (1): selenium binding (GO:0008430)

GO Cellular Component (5): extracellular region (GO:0005576), platelet dense granule lumen (GO:0031089), extracellular exosome (GO:0070062), obsolete extracellular space (GO:0005615), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Response to elevated platelet cytosolic Ca2+	1
Hemostasis	1
Platelet activation, signaling and aggregation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
metabolic process	1
response to stress	1
central nervous system development	1
animal organ development	1
head development	1
behavior	1
multicellular organism development	1
multicellular organismal process	1
response to chemical	1
growth	1
regulation of biological process	1
small molecule binding	1
secretory granule lumen	1
platelet dense granule	1
extracellular vesicle	1

Protein interactions and networks

STRING

1863 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SELENOP	GPX3	P22352	892
SELENOP	GPX2	P18283	859
SELENOP	SMCP	P49901	839
SELENOP	LRP8	Q14114	837
SELENOP	SECISBP2	Q96T21	828
SELENOP	TXN	P10599	813
SELENOP	SELENOK	Q9Y6D0	799
SELENOP	SELENOF	O60613	782
SELENOP	SELENOS	Q9BQE4	782
SELENOP	SELENOW	P63302	779
SELENOP	SELENOM	Q8WWX9	736
SELENOP	SEPHS2	Q99611	728
SELENOP	SELENON	Q9NZV5	723
SELENOP	SELENOT	P62341	721
SELENOP	TXNRD1	Q16881	721

IntAct

20 interactions, top by confidence:

A	B	Type	Score
EGFR	SELENOP	psi-mi:“MI:0915”(physical association)	0.550
SELENOP	EGFR	psi-mi:“MI:0915”(physical association)	0.550
	LECT2	psi-mi:“MI:0915”(physical association)	0.400
	CD5L	psi-mi:“MI:0915”(physical association)	0.400
	SELENOP	psi-mi:“MI:0915”(physical association)	0.370
SELENOP		psi-mi:“MI:0915”(physical association)	0.370
SELENOP	EP300	psi-mi:“MI:0915”(physical association)	0.370
S	IGLL5	psi-mi:“MI:0914”(association)	0.350
SELENOP	glgA	psi-mi:“MI:0915”(physical association)	0.000
rpoC	SELENOP	psi-mi:“MI:0915”(physical association)	0.000
	SELENOP	psi-mi:“MI:0915”(physical association)	0.000
SELENOP	mnmE	psi-mi:“MI:0915”(physical association)	0.000
SELENOP		psi-mi:“MI:0915”(physical association)	0.000
SELENOP	YPMT1.25Ac	psi-mi:“MI:0915”(physical association)	0.000
SELENOP	mtfA	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (7): SEPP1 (Affinity Capture-MS), SEPP1 (Two-hybrid), SEPP1 (Reconstituted Complex), SEPP1 (PCA), SEPP1 (Two-hybrid), SEPP1 (Two-hybrid), SEPP1 (Two-hybrid)

ESM2 similar proteins: A1A5Q6, A6NF34, A6NNT2, B0BF33, D3ZF92, O43278, O75509, O88393, P08920, P08921, P25236, P26342, P35054, P49907, P49908, P51843, P70274, P70503, P79386, Q03167, Q05469, Q13342, Q1LVK9, Q4JF29, Q4R7B7, Q5F378, Q5QGU6, Q5R8W9, Q61066, Q6AY06, Q6P7C7, Q6S545, Q8BHP7, Q8BVM2, Q8VHF2, Q91ZV2, Q921T2, Q96PD2, Q99P91, Q99PS8

Diamond homologs: P25236, P49907, P49908, P70274, Q5R8W9, Q98SV0, Q98SV1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

31 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	20
Likely benign	6
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

839 predictions. Top by Δscore:

Variant	Effect	Δscore
5:42801330:GT:G	acceptor_gain	1.0000
5:42808153:AGATG:A	donor_gain	1.0000
5:42808270:A:AC	donor_gain	1.0000
5:42808271:C:CC	donor_gain	1.0000
5:42811830:A:AC	donor_gain	1.0000
5:42811831:C:CC	donor_gain	1.0000
5:42811834:A:AC	donor_gain	1.0000
5:42811835:C:CC	donor_gain	1.0000
5:42811835:CA:C	donor_gain	1.0000
5:42811835:CACAA:C	donor_gain	1.0000
5:42801328:GAGT:G	acceptor_gain	0.9900
5:42801330:GTC:G	acceptor_loss	0.9900
5:42801332:C:CC	acceptor_gain	0.9900
5:42801332:CTGG:C	acceptor_loss	0.9900
5:42801333:T:C	acceptor_loss	0.9900
5:42808149:A:AC	donor_gain	0.9900
5:42808150:C:CC	donor_gain	0.9900
5:42811831:CT:C	donor_loss	0.9900
5:42811832:T:TC	donor_loss	0.9900
5:42811834:A:T	donor_loss	0.9900
5:42811835:C:CA	donor_loss	0.9900
5:42811835:CACA:C	donor_gain	0.9900
5:42811860:T:TA	donor_gain	0.9900
5:42801338:CAAA:C	acceptor_loss	0.9800
5:42806925:T:TA	donor_gain	0.9800
5:42808154:G:C	donor_gain	0.9800
5:42808367:C:G	acceptor_loss	0.9800
5:42808368:T:G	acceptor_loss	0.9800
5:42811830:AC:A	donor_loss	0.9800
5:42811833:TAC:T	donor_gain	0.9800

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000553014 (5:42809359 C>T), RS1000650294 (5:42800588 A>T), RS1000901689 (5:42809703 G>A,C,T), RS1001221319 (5:42805880 A>C,G), RS1001264312 (5:42813450 G>C), RS1001924939 (5:42801814 G>C), RS1001961792 (5:42801260 C>T), RS1002169245 (5:42807657 T>C), RS1002595635 (5:42804781 A>C,G), RS1003316300 (5:42804351 C>A), RS1003597775 (5:42803372 C>G), RS1003651574 (5:42802962 A>T), RS1004422883 (5:42799952 T>C), RS1004578878 (5:42806484 T>C), RS1004665931 (5:42806989 G>A)

Disease associations

OMIM: gene MIM:601484 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST012227_1346	Hip circumference adjusted for BMI	1.000000e-13

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs6136	SELP		0.00	0

CTD chemical–gene interactions

98 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	6
Estradiol	affects expression, affects cotreatment, decreases expression, increases expression	5
Sodium Selenite	decreases reaction, increases secretion, affects cotreatment, decreases expression, increases expression	5
Selenium	affects reaction, affects response to substance, affects binding, increases abundance, increases expression (+1 more)	4
methylmercuric chloride	decreases expression	3
trichostatin A	affects cotreatment, increases expression	3
Air Pollutants	decreases expression, increases abundance	3
Mercury	increases abundance, affects abundance, affects binding, decreases response to substance, increases expression	3
Nickel	affects binding, decreases expression	3
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	affects expression, increases expression	3
Particulate Matter	decreases expression, increases abundance	3
sodium arsenite	decreases expression, increases expression, affects cotreatment	2
cupric chloride	decreases expression	2
mercuric bromide	increases expression, affects cotreatment	2
entinostat	affects cotreatment, increases expression	2
2,2’,4,4’-tetrabromodiphenyl ether	increases expression, decreases expression	2
Resveratrol	decreases reaction, increases expression, affects cotreatment, decreases expression	2
Arsenic Trioxide	increases expression, decreases expression	2
Vorinostat	increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Acetaminophen	decreases expression	2
Benzo(a)pyrene	decreases expression, decreases methylation	2
Dexamethasone	affects cotreatment, increases expression	2
Ozone	increases expression	2
Phenylmercuric Acetate	increases expression, affects cotreatment	2
Dihydrotestosterone	increases expression, decreases reaction	2
Tobacco Smoke Pollution	decreases expression	2
Metribolone	increases expression, decreases reaction	2
Aflatoxin B1	decreases expression, decreases methylation	2
bisphenol F	affects cotreatment, increases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1QG	Abcam K-562 SELENOP KO	Cancer cell line	Female
CVCL_D2M2	Abcam Raji SELENOP KO	Cancer cell line	Male
CVCL_WQ50	Abcam Jurkat SELENOP KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.